SiRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide

Journal of Investigative Dermatology

Volumn 131, Issue 2, 2011, Pages 453-460

  Zuckerman, Jonathan E ^a,b   Hsueh, Teli ^a   Koya, Richard C ^a   Davis, Mark E ^b   Ribas, Antoni ^a,c  

^a UCLA MEDICAL CENTER   (United States)

^b California Institute of Technology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; TEMOZOLOMIDE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; PRIORITY JOURNAL; RNA INTERFERENCE;

EID: 78651388588     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.310     Document Type: Article

References (24)

1. Aghi M, Rabkin S, Martuza RL (2006) Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98:38-50
2. Augustine CK, Yoo JS, Potti A et al. (2009) Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res 15:502-10
3. Avolio TM, Lee Y, Feng N et al. (2007) RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo. Anti-Cancer Drugs 18:377-88
4. Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chem 18:456-68
5. Chen M, Osman I, Orlow SJ (2009) Antifolate activity of pyrimethamine enhances temozolomide-induced cytotoxicity in melanoma cells. Mol Cancer Res 7:703-12
6. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-81
7. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharmaceutics 6:659-68
8. Davis ME, Zuckerman JE, Choi CH et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067-70
9. Desai AA, Schilsky RL, Young A et al. (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16:958-65
10. Duxbury MS, Ito H, Zinner MJ et al. (2004) RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23:1539-48
11. Engstrom Y, Eriksson SJildevik I etal. (1985) Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 260:9114-6
12. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-7
13. Heidel JD, Liu JY, Yen Y et al. (2007a) Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13:2207-15
14. Heidel JD, Yu Z, Liu JY etal. (2007b) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715-21
15. Søndergaard JN, Nazarian R, Qi W et al. (2010) Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific BRAF inhibitor PLX4032/RG7204. J Transl Med. (in press)
16. Juhasz A, Vassilakos A, Chew HK et al. (2006) Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep 15:1299-304
17. Lee Y, Vassilakos A, Feng N et al. (2003) GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Research 63:2802-11
18. Lin ZP, Belcourt MF, Cory JG et al. (2004) Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem 279:27030-8
19. Mhaidat NM, Zhang XD, Allen J et al. (2007) Temozolomide induces senescence but not apoptosis in human melanoma cells. Br J Cancer 97:1225-33
20. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
21. Reid G, Wallant NC, Patel R et al. (2009) Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. J RNAi Gene Silencing 5:321-30
22. Rietschel P, Wolchok JD, Krown S et al. (2008) Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 26:2299-304
23. Shao J, Zhou B, Chu B et al. (2006) Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 6:409-31
24. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012